» Articles » PMID: 33767592

Anterior Gradient 2 Increases Long-chain Fatty Acid Uptake Via Stabilizing FABP1 and Facilitates Lipid Accumulation

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2021 Mar 26
PMID 33767592
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Anterior gradient 2 (AGR2), a protein disulfide isomerase (PDI), is a well-established oncogene. Here, we found that mice had a decreased fat mass and hepatic and serum lipid levels compared with their wild-type littermates after fasting, and exhibited reduced high-fat diet (HFD)-induced fat accumulation. Transgenic mice overexpressing AGR2 (/Tg) readily gained fat weight on a HFD but not a normal diet. Proteomic analysis of hepatic samples from 2 mice revealed that depletion of AGR2 impaired long-chain fatty acid uptake and activation but did not affect hepatic lipogenesis. Further investigations led to the identification of several effector substrates, particularly fatty acid binding protein-1 (FABP1) as essential for the AGR2-mediated effects. AGR2 was coexpressed with FABP1, and knockdown of AGR2 resulted in a reduction in FABP1 stability. Physical interactions of AGR2 and FABP1 depended on the PDI motif in AGR2 and the formation of a disulfide bond between these two proteins. Overexpression of AGR2 but not a mutant AGR2 protein lacking PDI activity suppressed lipid accumulation in cells lacking FABP1. Moreover, AGR2 deficiency significantly reduced fatty acid absorption in the intestine, which might be resulted from decreased fatty acid transporter CD36 in mice. These findings demonstrated a novel role of AGR2 in fatty-acid uptake and activation in both the liver and intestine, which contributed to the AGR2-mediated lipid accumulation, suggesting that AGR2 is an important regulator of whole-body lipid metabolism and down-regulation of AGR2 may antagonize the development of obesity.

Citing Articles

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment.

Qu S, Jia W, Nie Y, Shi W, Chen C, Zhao Z Biomolecules. 2024; 14(7).

PMID: 39062458 PMC: 11275012. DOI: 10.3390/biom14070743.


Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.

Tang W, Sun G, Ji G, Feng T, Zhang Q, Cao H J Immunother Cancer. 2023; 11(11).

PMID: 38007237 PMC: 10679975. DOI: 10.1136/jitc-2023-007030.


Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling.

Zhang B, Lu J, Jiang Y, Feng Y Immun Inflamm Dis. 2023; 11(8):e947.

PMID: 37647445 PMC: 10436697. DOI: 10.1002/iid3.947.


AGR2-induced cholesterol synthesis drives lovastatin resistance that is overcome by combination therapy with allicin.

Sheng N, Wang Y, Wang C, Jia M, Niu H, Lu Q Acta Pharmacol Sin. 2022; 43(11):2905-2916.

PMID: 35459869 PMC: 9622889. DOI: 10.1038/s41401-022-00909-3.

References
1.
Wang Z, Schraw T, Kim J, Khan T, Rajala M, Follenzi A . Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol. 2007; 27(10):3716-31. PMC: 1899995. DOI: 10.1128/MCB.00931-06. View

2.
Hotamisligil G, Bernlohr D . Metabolic functions of FABPs--mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015; 11(10):592-605. PMC: 4578711. DOI: 10.1038/nrendo.2015.122. View

3.
Guo H, Zhu Q, Yu X, Merugu S, Mangukiya H, Smith N . Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene. 2017; 36(36):5098-5109. DOI: 10.1038/onc.2017.132. View

4.
Yang L, Zhao D, Ren J, Yang J . Endoplasmic reticulum stress and protein quality control in diabetic cardiomyopathy. Biochim Biophys Acta. 2014; 1852(2):209-18. DOI: 10.1016/j.bbadis.2014.05.006. View

5.
Wang X, Du H, Shao S, Bo T, Yu C, Chen W . Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis. Hepatology. 2018; 68(1):62-77. DOI: 10.1002/hep.29788. View